drugset
drugset / Trial / NCT07262476

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

NCT07262476 ↗

Phase 3 Recruiting 258 enrolled Minghui Pharmaceutical (Hangzhou) Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.

Timeline

Start
2026-01-09
Primary completion
2029-01-31
Completion
2030-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MHB018A Monoclonal antibody 450 mg Subcutaneous

Indications

endocrine exophthalmos